DaVita Inc. (NYSE:DVA) Receives $161.80 Average Price Target from Analysts

Shares of DaVita Inc. (NYSE:DVA) have been given an average rating of “Hold” by the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $161.80.

A number of equities research analysts recently commented on the company. Barclays boosted their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial lifted their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th.

DaVita Price Performance

Shares of NYSE:DVA opened at $155.06 on Friday. The company has a market capitalization of $12.71 billion, a P/E ratio of 16.73, a P/E/G ratio of 0.86 and a beta of 0.90. DaVita has a 1-year low of $103.40 and a 1-year high of $169.51. The firm’s 50 day simple moving average is $156.43 and its two-hundred day simple moving average is $151.15. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter in the prior year, the business posted $2.85 EPS. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. Research analysts expect that DaVita will post 9.71 EPS for the current fiscal year.

Institutional Investors Weigh In On DaVita

Hedge funds and other institutional investors have recently made changes to their positions in the company. MML Investors Services LLC grew its stake in shares of DaVita by 1.3% during the third quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock valued at $869,000 after buying an additional 68 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in DaVita by 1.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company’s stock valued at $776,000 after acquiring an additional 70 shares during the last quarter. Wedmont Private Capital increased its stake in DaVita by 4.4% in the third quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock worth $280,000 after purchasing an additional 75 shares during the period. Blue Trust Inc. lifted its position in shares of DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares during the last quarter. Finally, First Trust Direct Indexing L.P. boosted its stake in shares of DaVita by 2.9% during the third quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company’s stock valued at $500,000 after purchasing an additional 86 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.